Eyeglasses and contact lenses: Medicare will not pay for eyeglasses or contact lenses, with one exception: If you have had a ...

Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases ...

- Cash Position: Cash and cash equivalents were $101.6 million as of March 31, 2025, compared to $34.6 million as of December 31, 2024, bolstered by $76.4 million in gross proceeds from the first ...

Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in ...

Cognition Therapeutics has announced positive topline outcomes from the Phase II MAGNIFY trial of zervimesine in adult ...

D Molecular Therapeutics, Inc.’s FDMT share price has dipped by 5.25%, which has investors questioning if this is right time to buy.

Cognition Therapeutics (CGTX) reported preclinical data this week at the Association for Research in Vision and Ophthalmology showing the ...

Huge numbers of Brits could be driving without having notified the DVLA about their pre-existing conditions that should be ...

Aiming to enhance the eye care treatment, Sealdah Division of Eastern Railway has introduced Advanced OCT-A Technology at BR Singh Hospital.

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expect ...

Learn more about whether Alvotech or BioCryst Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen's senior management team will host the call, which ...